Stay updated on CTX120 in RR Multiple Myeloma: Safety and Efficacy Clinical Trial

Sign up to get notified when there's something new on the CTX120 in RR Multiple Myeloma: Safety and Efficacy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CTX120 in RR Multiple Myeloma: Safety and Efficacy Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    6 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:57:39.000Z thumbnail image
  6. Check
    14 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the safety and efficacy evaluation of CTX120 in subjects with relapsed or refractory multiple myeloma.
    Difference
    0.1%
    Check dated 2024-06-06T14:41:16.000Z thumbnail image
  7. Check
    28 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as age, health condition, and prior treatments for relapsed or refractory multiple myeloma. Previously, this section only indicated that no information was provided.
    Difference
    23%
    Check dated 2024-05-22T21:32:37.000Z thumbnail image
  8. Check
    50 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:35:30.000Z thumbnail image

Stay in the know with updates to CTX120 in RR Multiple Myeloma: Safety and Efficacy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CTX120 in RR Multiple Myeloma: Safety and Efficacy Clinical Trial page.